More evidence links MCP-1 levels to cardiovascular mortality

Reuters Health - 12/11/2020 - Higher circulating levels of monocyte-chemoattractant protein-1 (MCP-1) are associated with higher long-term cardiovascular mortality in individuals free of overt heart disease, a meta-analysis suggests. "By complementing evidence from previous genetic and experimental studies, these results provide additional support for a key role of MCP-1 in cardiovascular disease development," note Dr. Martin Dichgans of Ludwig-Maximilians-University in Munich and colleagues in JAMA Cardiology. The meta-analysis included seven cohort studies involving more than 21,000 individuals without known heart disease (mean age, 54; 47% men). Mean follow-up was 15.3 years. In adjusted models (age, sex, race/ethnicity), higher baseline MCP-1 levels were associated with increased risk of coronary heart disease (hazard ratio per one standard-deviation increment in MCP-1 levels, 1.06), nonfatal myocardial infarction (HR, 1.07), and cardiovascular death (HR,...

Please login to read the full text of the article.

If you have no account yet, please register now.

Posted on 12 November, 202020 November, 2020